Although no vaccine product is clinically approved as a therapeutic vaccine against hypertension, Ang II DNA vaccine is currently under clinical investigation (phase I/II trial) and expected to be proven its safety and effectiveness. The gene discussed is AGT; the disease is hypertensive disorder.